Intra-articular Sodium Hyaluronate has an established place in the symptomatic treatment of osteoarthritis (OA). A treatment cycle with OSTENIL, an isotonic solution of highly purified sodium hyaluronate developed specifically for the treatment of OA, helps restore the synovial homeostasis of the affected joint, thereby improving the viscoelastic properties of the synovial fluid and restoring the lubricating and shock absorbing functions. The net result is a decrease in pain and an improvement in joint mobility which may last for several months.
Recently, TRB Chemedica have launched OSTENIL Plus as an innovative single injection option, in addition to the standard version of OSTENIL. The novelty of OSTENIL Plus lies in the combination of high concentration of sodium hyaluronate + mannitol. The aim of developing OSTENIL Plus was to allow a flexible treatment scheme with fewer injections and longer periods between injections, compared to standard therapy.
OSTENIL and OSTENIL Plus do not contain any avian proteins, and both have been documented to be well tolerated.
References and further information are available from:
